Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944640 | 1.00 | TRPV1 (0.52) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL4139146 | 0.94 | TRPV1 (0.50) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL4139143 | 0.94 | TRPV1 (0.50) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL4139148 | 0.94 | TRPV1 (0.50) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL3940207 | 0.92 | TRPV1 (0.59) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL3940216 | 0.92 | TRPV1 (0.59) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL3948621 | 0.90 | TRPV1 (0.56) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL3948623 | 0.90 | TRPV1 (0.56) | TRPV1NPY5RCHEK1PIM1CDK8 | |
| SCHEMBL3948380 | 0.88 | TRPV1 (0.58) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3948385 | 0.88 | TRPV1 (0.58) | TRPV1CHEK1PIM1CDK8GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | TRPV1 2741/4885NPY5R 279/4885CHEK1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.